1. Brix G, Lechel U, Beyer T, Glatting G, Münzing W, Ziegler S. Exposition von Patienten bei Ganzkörper-Untersuchungen an PET/CT-System. Med Phys 2004:282 - 3.
  2. Buchmann I, Neumaier B, Schreckenberger M, Reske SN. (18F)3´-deoxy-3´-fluorothymidine-PET in NHL patients. whole-body biodistribution and imaging of lymphoma manifestations--a pilot study. Cancer Biother Radiopharm 2004;19(4):436-42.
  3. Buck A, Schirrmeister H, Mattfeld T, Reske SN. Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging 2004;31:80-7.
  4. Buck A, Glatting G, Reske SN. Quantification of 18F-FDG uptakein non-small cell lung cancer: a feasible prognostic marker? Journal of nuclear medicine 2004;45(8):1274-6.
  5. Buck AK, Reske SN. Cellular Origin and Molecular Mechanisms of 18F-FDG Uptake: Is There a Contribution of the Endothelium? J Nucl Med 2004;45:461-3.
  6. Friesen C, Kiess Y, Debatin KM. A critical role of glutathione in determining apoptosis sensitivity and resistance in leukemia cells. Cell Death Differ 2004;11:73 - 85.
  7. Gangitano M, Mottaghy FM, Pascual-Leone A. Modulation of premotor mirror neuron activity during observation of unpredictable grasping movements. European Journal of Neuroscience 2004;20:2193 - 202.
  8. Glatting G, Mottaghy FM, Baune A, Sommer TF, Landwehrmeyer GB, Reske SN. Improving binding potential analysis in [11C]raclopride PET studies using cluster analysis. Med Phys 2004;31:902-6.
  9. Golaszewski SM, Siedentopf CM, Koppelstaetter F, Rhomberg P, G.M. G, Schlager A et al. Modulatory effects on human sensorimotor cortex by whole-hand afferent electrical stimulation. Neurology 2004;62:2262 - 9.
  10. Halter G, Buck AK, Schirrmeister H, Aksoy E, Liewald F, Glatting G et al. Lymph node staging in lung cancer using [18F]FDG-PET. Thorac Cardiovasc Surg 2004;52:96-101.
  11. Halter G, Buck AK, Schirrmeister H, Wurziger I, Liewald F, Glatting G et al. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions? J Thorac Cardiovasc Surg 2004;127:1093-9.
  12. Henkel K, Karitzky J, Schmid M, Mader I, Glatting G, Unger JW et al. Imaging of activated microglia with PET and [11C]PK 11195 in corticobasal degeneration. Mov Disord 2004;19:817-21.
  13. Hetzel M, Hetzel J, Arslandemir C, Nuessle K, Schirrmeister H. Reliability of symptoms to determine use of bone scans to identify bone metastases in lung cancer: prospective study. Brit Med J 2004;328:1051 -2.
  14. Hetzel M, Buck A. Staging of non-small-cell lung cancer with integrated Pet and CT. N Engl J Med 2004;349:1188-90.
  15. Jager H, Dreker T, Buck A, Giehl K, Gress T, Grissmer S. Blockage of intermediate-conductance Ca2+-activated K+ channels inhibit human pancreatic cancer cell growth in vitro. Mol Pharmacol 2004;65:630-8.
  16. Unterrainer JM, Rahm B, Kaller CP, Ruff CC, Spreer J, Krause BJ, Schwarzwald R, Hautzel H, Halsband U. When Planning Fails: Individual Differences and Error-related Brain Activity in Problem Solving. Cerebral Cortex 2004;14:1390 -7.
  17. Kull T, Ruckgaber J, Weller R, Reske SN, Glatting G. Quantitative Imaging of Yttrium-86 PET with the ECAT EXACT HR+ in 2D Mode. Cancer Biother Radiopharm 2004;19:482-90.
  18. Reske SN, Dankerl A, Glatting G, Mottaghy FM, Blumstein NM. [Significance of PET for ENT-tumors]. Laryngorhinootologie 2004;83:391-406.
  19. Reuter S, Buck A, Manfras B, Kratzer W, Seitz HM, Darge K et al. Structured treatment interruption in patients with alveolar echinococcosis. Hepatology 2004;39:509-17.
  20. Ringhoffer M, Wiesneth M, Harsdorf S, Schlenk RF, Schmitt A, Reinhardt PP et al. CD34 cell selection of peripheral blood progenitor cells using the ClinicMACS device for allogeneic transplantation: clinical results in 102 patients. Brit J Haematol 2004;126(4):527-35.
  21. Schiffer F, Mottaghy FM, Vimalb RLP, Renshaw PF, Cowanb R, Pascual-Leone A et al. Lateral visual field stimulation reveals extrastriate cortical activation in the contralateral hemisphere: an fMRI study. Psychiatry Research Neuroimaging 2004;131:1 - 9.
  22. Schirrmeister H, Kotzerke J, Vogl F, Buck A, Czech N, Koretz K et al. Prospective evaluation of factors influencing success rates of sentinel node biopsy in 814 breast cancer patients. Cancer Biother Radiopharm 2004;19:784-90.
  23. Schirrmeister H, Hetzel M, Hetzel J, Habig T, Schumann C, Bommer M et al. Fibrinous Tracheitis: An Uncommon Manifestation of Hodgkin's Lymphoma. Journal of Clinical Oncology 2004:3642 - 3.
  24. Schirrmeister H, Arslandemir C, Glatting G, Mayer-Steinacker R, Bommer M, Dreinhofer K et al. Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2004;31:964-8.
  25. Schonfeldt-Lecuona C, Juengling FD, Connemann BJ, Reske SN, Spitzer M, Kassubek J. Complete dopamine D2 receptor occupancy without extrapyramidal side effects under benperidol. J Clin Psychopharmacol 2004;24:97-8.
  26. Shen C, Reske SN. Adenovirus-delivered siRNA. Humana Press 2004;252:523-32.